Debiopharm, ITM ink €300M licensing deal for cancer treatment
Debiopharm and ITM announced a licensing deal for a radiopharmaceutical treatment that’s being investigated in several cancers. Debiopharm, which is based in Switzerland, is eligible … Sign up to read this article for free. Get …